Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336

Blood

Volumn 97, Issue 5, 2001, Pages 1399-1403

  Reichert, Anja ^b   Heisterkamp, Nora ^b   Daley, George Q ^b   Groffen, John ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; TRANSGENIC MOUSE;

EID: 0035282735     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1399     Document Type: Article

References (24)

1. Outcome of Philadelphia chromosome-positive adult acute lymphpoblastic leukemia
2. Bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL)
3. Requirement for c-ras proteins during viral oncogene transformation
4. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: Implication for RAS dependent Philadelphia chromosome positive cell growth
5. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
6. Protein isoprenylation and methylation at carboxyl terminal cysteine residues
7. Endomembrane trafficking of Ras: The CAAX motive targets proteins to the ER and Golgi
8. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
9. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
10. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and human
11. Cell growth inhibition by farnesyltransferase inhibitor is mediated by gain of geranylgeranylated RhoB
12. Acute leukemia in bcr/abl transgenic mice
13. Restricted oncogenicity of BCR/ABL p190 in transgenic mice
14. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice
15. IFN-α treatment of P190 BCR/ABL transgenic mice
16. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice
17. (+)-4-[2[4-(8-Chloro-3, 10-dibromo-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1- piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
18. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
19. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
20. Clonal characteristics of acute lymphoblastic cells derived from bcr/abl p190 transgenic mice
21. Reversibility of acute B-cell leukemia induced by BCR-ABL1
22. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
23. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis